FMT

FMT

2939 bookmarks
Custom sorting
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis - PubMed
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis - PubMed
Multiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function …
·pubmed.ncbi.nlm.nih.gov·
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis - PubMed
Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives - PubMed
Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives - PubMed
This review summarizes the application of synthetic biology in intestinal microecology-based therapeutics for major chronic diseases and discusses the opportunities and challenges in the above process, providing clinical possibilities of synthetic biology technology applied in microecological therap …
·pubmed.ncbi.nlm.nih.gov·
Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives - PubMed
Microbiome dynamics in rheumatic diseases - PubMed
Microbiome dynamics in rheumatic diseases - PubMed
A deeper comprehension of the microbiome's connection to rheumatism holds potential for enhancing disease diagnosis and treatment. Targeted therapeutic approaches, including probiotics, fecal microbiota transplantation, and combination therapies with medications, offer promising avenues for disease …
·pubmed.ncbi.nlm.nih.gov·
Microbiome dynamics in rheumatic diseases - PubMed
Gut Frailty: Its Concept and Pathogenesis - PubMed
Gut Frailty: Its Concept and Pathogenesis - PubMed
Although the concept of gut frailty has not yet gained widespread recognition, we hope to propose more practical screening methods, diagnostic approaches, and specific interventions in the future.
·pubmed.ncbi.nlm.nih.gov·
Gut Frailty: Its Concept and Pathogenesis - PubMed
Company Who Developed Oral Live Biotherapeutic Reports Earnings
Company Who Developed Oral Live Biotherapeutic Reports Earnings
Seres Therapeutics reported its financials recently including the performance of it therapy, Vowst, as well as updates on its business and one of its investigational therapies.
·news.google.com·
Company Who Developed Oral Live Biotherapeutic Reports Earnings
Investigational non-antibiotic therapeutics for infections in hematopoietic cell transplant recipients and patients with hematologic malignancies receiving cellular therapies - PubMed
Investigational non-antibiotic therapeutics for infections in hematopoietic cell transplant recipients and patients with hematologic malignancies receiving cellular therapies - PubMed
In the age of progressive antimicrobial resistance and increased difficulty combating infections in immunocompromised hosts, there has been renewed interest in the use of nontraditional therapeutics for infections. Herein, we review the use of investigational non-pharmaceutical anti-infective agents …
·pubmed.ncbi.nlm.nih.gov·
Investigational non-antibiotic therapeutics for infections in hematopoietic cell transplant recipients and patients with hematologic malignancies receiving cellular therapies - PubMed
Therapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases - PubMed
Therapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases - PubMed
While emerging evidence highlights the significance of gut microbiome in gastrointestinal infectious diseases, treatments like Fecal Microbiota Transplantation (FMT) and probiotics are gaining popularity, especially for diarrhea patients. However, the specific role of the gut microbiome in different …
·pubmed.ncbi.nlm.nih.gov·
Therapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases - PubMed
Understanding the Gut-Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders - PubMed
Understanding the Gut-Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders - PubMed
The gut-brain axis (GBA) is a complex bidirectional communication network connecting the gut and brain. It involves neural, immune, and endocrine communication pathways between the gastrointestinal (GI) tract and the central nervous system (CNS). Perturbations of the GBA have been reported in many n …
·pubmed.ncbi.nlm.nih.gov·
Understanding the Gut-Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders - PubMed
Microbiota-Gut-Brain Axis and Antidepressant Treatment - PubMed
Microbiota-Gut-Brain Axis and Antidepressant Treatment - PubMed
In the treatment of depressive disorders, conventional antidepressant therapy has been the mainstay of clinical management, along with well-established nonpharmacological interventions such as various kinds of psychotherapy. Over the last 2 decades, there has been considerable interest in the role o …
·pubmed.ncbi.nlm.nih.gov·
Microbiota-Gut-Brain Axis and Antidepressant Treatment - PubMed
What Specialties are Using Live Biotherapeutic Products?
What Specialties are Using Live Biotherapeutic Products?
With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.
·contagionlive.com·
What Specialties are Using Live Biotherapeutic Products?
The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA - PubMed
The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA - PubMed
The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA
·pubmed.ncbi.nlm.nih.gov·
The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA - PubMed
Novel pharmacological developments in the management of paediatric inflammatory bowel disease: Time for guideline update - A narrative review - PubMed
Novel pharmacological developments in the management of paediatric inflammatory bowel disease: Time for guideline update - A narrative review - PubMed
While many developments have been achieved with novel pharmacological treatments to manage IBD, ongoing research is required to confirm their effectiveness and safety in the paediatric age. Extending the licence of novel treatments to children will be crucial to tackle the increasing loss of respons …
·pubmed.ncbi.nlm.nih.gov·
Novel pharmacological developments in the management of paediatric inflammatory bowel disease: Time for guideline update - A narrative review - PubMed
Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering - PubMed
Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering - PubMed
Recent developments in sequencing technology and analytical approaches have allowed researchers to show that the healthy gut microbiome is very varied and capable of performing a wide range of tasks. The importance of gut microbiota in controlling immunological, neurological, and endocrine function …
·pubmed.ncbi.nlm.nih.gov·
Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering - PubMed
Microbiome Therapeutics Market Size to Hit $813.38 Million, Globally, by 2030 - Exclusive Report by The Insight Partners
Microbiome Therapeutics Market Size to Hit $813.38 Million, Globally, by 2030 - Exclusive Report by The Insight Partners
The global microbiome therapeutics market is growing at a CAGR of 10.1% from 2022 to 2030.Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements i
·news.google.com·
Microbiome Therapeutics Market Size to Hit $813.38 Million, Globally, by 2030 - Exclusive Report by The Insight Partners
Role of the microbiota in response to and recovery from cancer therapy - PubMed
Role of the microbiota in response to and recovery from cancer therapy - PubMed
Our understanding of how the microbiota affects the balance between response to and failure of cancer treatment by modulating the tumour microenvironment and systemic immune system has advanced rapidly in recent years. Microbiota-targeting interventions in patients with cancer are an area of intensi …
·pubmed.ncbi.nlm.nih.gov·
Role of the microbiota in response to and recovery from cancer therapy - PubMed
Effect of probiotics and fecal microbiota transplantation in dirty rats with established primary liver cancer - PubMed
Effect of probiotics and fecal microbiota transplantation in dirty rats with established primary liver cancer - PubMed
Background: The modulating effects of probiotics and fecal microbiota transplantation (FMT) on gut flora and their direct antitumor effects remain unclear in dirty rats with established primary liver cancer. Materials & methods: Probiotics (VSL#3), FMT or tap water were administrat …
·pubmed.ncbi.nlm.nih.gov·
Effect of probiotics and fecal microbiota transplantation in dirty rats with established primary liver cancer - PubMed
Gut microbiome-targeted therapies for Alzheimer's disease - PubMed
Gut microbiome-targeted therapies for Alzheimer's disease - PubMed
The advent of high-throughput 'omics' technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer's disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract and the …
·pubmed.ncbi.nlm.nih.gov·
Gut microbiome-targeted therapies for Alzheimer's disease - PubMed
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease - PubMed
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease - PubMed
Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of …
·pubmed.ncbi.nlm.nih.gov·
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease - PubMed
Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation - PubMed
Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation - PubMed
Clostridioides difficile infection (CDI) is considered to be one of the most frequent causes of bacterial infectious diarrhea in nosocomial settings. The prolonged hospitalization in bed-ridden conditions and the frequent administration of antibiotic therapy are usually encountered among the …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation - PubMed
Microbiota in cancer: molecular mechanisms and therapeutic interventions - PubMed
Microbiota in cancer: molecular mechanisms and therapeutic interventions - PubMed
The diverse bacterial populations within the symbiotic microbiota play a pivotal role in both health and disease. Microbiota modulates critical aspects of tumor biology including cell proliferation, invasion, and metastasis. This regulation occurs through mechanisms like enhancing genomic damage, hi …
·pubmed.ncbi.nlm.nih.gov·
Microbiota in cancer: molecular mechanisms and therapeutic interventions - PubMed
Surgery-induced gut microbial dysbiosis promotes cognitive impairment via regulation of intestinal function and the metabolite palmitic amide - PubMed
Surgery-induced gut microbial dysbiosis promotes cognitive impairment via regulation of intestinal function and the metabolite palmitic amide - PubMed
Gut microbial dysbiosis in mice after surgery is a key mechanism leading to cognition dysfunction, which disrupts the intestinal barrier and metabolic abnormalities, resulting in neuroinflammation and dendritic spine loss. Intestinal barrier damage and high level of palmitic amide in old mice may be …
·pubmed.ncbi.nlm.nih.gov·
Surgery-induced gut microbial dysbiosis promotes cognitive impairment via regulation of intestinal function and the metabolite palmitic amide - PubMed
How Poop Transplants Battle Multidrug-Resistant Bacteria
How Poop Transplants Battle Multidrug-Resistant Bacteria
In hospital settings, multidrug-resistant organisms (MDRO) are a major threat to patient safety. A new study has taken a different approach to eradicating MDROs. They’ve developed a method that fights microbes with other microbes.
·news.google.com·
How Poop Transplants Battle Multidrug-Resistant Bacteria
Efficacy and safety of fecal microbiota transplantation for the treatment of irritable bowel syndrome: an overview of overlapping systematic reviews - PubMed
Efficacy and safety of fecal microbiota transplantation for the treatment of irritable bowel syndrome: an overview of overlapping systematic reviews - PubMed
Aim: Evidence from overlapping systematic reviews (SRs) and meta-analyses (MAs) has yielded conflicting results on the treatment of irritable bowel syndrome (IBS) with fecal microbiota transplantation (FMT). To thoroughly gather, assess, and synthesize evidence on FMT for IBS, we carried out …
·pubmed.ncbi.nlm.nih.gov·
Efficacy and safety of fecal microbiota transplantation for the treatment of irritable bowel syndrome: an overview of overlapping systematic reviews - PubMed